Kura Oncology (NASDAQ:KURA) Insider Mollie Leoni Sells 8,180 Shares

Kura Oncology, Inc. (NASDAQ:KURA) insider Mollie Leoni sold 8,180 shares of the stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total transaction of $69,202.80. Following the sale, the insider owned 267,274 shares in the company, valued at approximately $2,261,138.04. This trade represents a 2.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Mollie Leoni also recently made the following trade(s):

• On Friday, November 14th, Mollie Leoni sold 15,485 shares of Kura Oncology stock. The shares were sold at an average price of $11.18, for a total value of $173,122.30.

Kura Oncology Stock Down 1.2%

NASDAQ:KURA opened at $8.47 on Wednesday. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.02. The stock has a 50 day moving average of $10.33 and a 200-day moving average of $9.05. The firm has a market capitalization of $737.06 million, a PE ratio of -3.42 and a beta of 0.25. Kura Oncology, Inc. has a 52 week low of $5.41 and a 52 week high of $12.49.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The company had revenue of $20.75 million for the quarter, compared to analyst estimates of $17.48 million. Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. Analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Kura Oncology News Roundup

Here are the key news stories impacting Kura Oncology this week:

• Negative Sentiment: Teresa Brophy Bair (insider) sold 11,208 shares at an average price of $8.46 for proceeds of $94,819.68; her post-sale holdings are 226,931 shares (down ~4.71%). Read More.
• Negative Sentiment: Francis Burrows (insider) sold 1,311 shares at $8.46 for proceeds of $11,091.06; post-sale holdings 32,424 shares (down ~3.89%). Read More.
• Negative Sentiment: Thomas James Doyle (SVP) sold 7,142 shares at $8.46 for proceeds of $60,421.32; post-sale holdings 145,167 shares (down ~4.69%). Read More.
• Negative Sentiment: Mollie Leoni (insider) sold 8,180 shares at $8.46 for proceeds of $69,202.80; post-sale holdings 267,274 shares (down ~2.97%). Read More.
• Negative Sentiment: Kathleen Ford (COO) sold 1,813 shares at $8.46 for proceeds of $15,337.98; post-sale holdings 153,560 shares (down ~1.17%). Read More.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a research report on Friday, December 5th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a report on Tuesday, January 13th. JMP Securities reiterated a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a research report on Monday, October 20th. Wedbush restated an “outperform” rating and issued a $38.00 target price (up from $36.00) on shares of Kura Oncology in a research report on Friday, November 14th. Finally, Leerink Partners set a $20.00 target price on Kura Oncology and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $28.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers raised its holdings in Kura Oncology by 0.9% during the third quarter. Rhumbline Advisers now owns 119,935 shares of the company’s stock worth $1,061,000 after purchasing an additional 1,039 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Kura Oncology by 9.5% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 20,993 shares of the company’s stock valued at $217,000 after purchasing an additional 1,825 shares in the last quarter. Flower City Capital increased its position in shares of Kura Oncology by 20.0% during the 4th quarter. Flower City Capital now owns 12,000 shares of the company’s stock valued at $125,000 after purchasing an additional 2,000 shares during the period. Profund Advisors LLC increased its position in shares of Kura Oncology by 11.1% during the 3rd quarter. Profund Advisors LLC now owns 24,835 shares of the company’s stock valued at $220,000 after purchasing an additional 2,478 shares during the period. Finally, Arizona State Retirement System raised its stake in shares of Kura Oncology by 15.8% in the 3rd quarter. Arizona State Retirement System now owns 20,481 shares of the company’s stock worth $181,000 after buying an additional 2,802 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.